milademetan

MDM2 inhibitor

Also Known As:

2,6-anhydro-5-((((3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-L-erythro-hexonamide; DS-3032; RAIN-32

Networked: 8 relevant articles (2 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - milademetan: 8
  - Pyridines: 88
    - milademetan: 8
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - milademetan: 8

Experts

1.	Tachibana, Masaya: 2 articles (11/2021 - 06/2021)
2.	Ananthapadmanabhan, Varsha: 1 article (01/2022)
3.	DeCaprio, James A: 1 article (01/2022)
4.	Doebele, Robert C: 1 article (01/2022)
5.	Frost, Thomas C: 1 article (01/2022)
6.	Gokhale, Prafulla C: 1 article (01/2022)
7.	Knott, Aine: 1 article (01/2022)
8.	Magliozzi, Brianna J: 1 article (01/2022)
9.	Soroko, Kara M: 1 article (01/2022)
10.	Tirunagaru, Vijaya G: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "Here, along with preclinical data for the efficacy of milademetan in WT p53 MCC tumors, we report several in vitro and in vivo models useful for future MCC studies." 01/01/2023 - "This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers. " 01/01/2023 - "This is the first phase I study report of milademetan monotherapy in relapsed/refractory (R/R) AML patients evaluating the safety, tolerability, pharmacokinetics, and preliminary tumor response for further clinical development. " 06/01/2021 - "Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study." 01/01/2022 - "Milademetan showed a dose-dependent inhibition of tumor growth in MKL-1 xenograft and patient-derived xenograft models. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2023 - "Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia." 11/01/2021 - "Milademetan is a small-molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including liposarcoma and acute myeloid leukemia. " 01/01/2023 - "A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis."
3.	Lymphoma (Lymphomas) 01/01/2023 - "In this first-in-human phase I study, patients with advanced solid tumors or lymphomas received milademetan orally once daily as extended/continuous (days 1-21 or 1-28 every 28 days) or intermittent (days 1-7, or days 1-3 and 15-17 every 28 days) schedules. " 06/01/2021 - "Future studies would be needed to further evaluate the potential safety, tolerability, and clinical activity of milademetan in patients with solid tumors and lymphomas. " 01/01/2023 - "A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas."
4.	Liposarcoma 01/01/2023 - "Notable single-agent activity with milademetan in dedifferentiated liposarcomas has prompted a randomized phase III trial (MANTRA)." 01/01/2023 - "Two MDM2 inhibitors, milademetan and BI907828, have both reached the optimal dosing and have shown promising efficacy in MDM2-amplified liposarcoma. " 01/01/2023 - "A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas." 11/01/2021 - "Milademetan is a small-molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including liposarcoma and acute myeloid leukemia. "
5.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2023 - "This study can inform future milademetan studies in hematologic malignancies."

Related Drugs and Biologics

1.	Cytarabine (Cytosar-U)
2.	venetoclax
3.	Biomarkers (Surrogate Marker)

Related Therapies and Procedures

1.	Therapeutics